Since this chronic PD mouse model exhibits both progressive dopaminergic neuron loss and vascular pathologies with reduced P-gp expression, preclinical studies with 1,25(OH)2D3 post-treatment would validate translational value of the VDR signaling pathway in treating diverse aspects of PD pathogenesis. This evidence concerns the gene PGP and Parkinson disease.